Peter Lynch fit · Growth at a reasonable price (GARP)
Is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) a Peter Lynch Stock?
Strong GARP candidate — growth at a reasonable price.
72/100
BProvável ação Lynch
5/6 critérios atendidos
Os critérios de Peter Lynch, aplicados a AMRX
PEG ≤ 1.0
chave—
EPS CAGR ≥ 15%
chave37.4%
Revenue CAGR ≥ 10%
37.6%
Net margin > 0
0.2%
Como AMRX pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$4.21B
P/L (TTM)
-
ROIC (TTM)
9.19%
Margem bruta
36.76%
Perguntas frequentes
What is AMRX's Peter Lynch fit score?
AMRX scores 72/100 on our Peter Lynch fit engine — grade B. Strong GARP candidate — growth at a reasonable price.
Does Peter Lynch actually own AMRX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends AMRX.
How often is this score updated?
AMRX's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Peter Lynch possua ou recomende AMRX pessoalmente.